Genvor to Participate in BioAgTech World Congress in Raleigh, North Carolina
- None.
- None.
CHAPEL HILL, NC / ACCESSWIRE / April 2, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, today announced that management will attend the 5th BioAgTech World Congress taking place April 22-26, 2024 in Raleigh, North Carolina.
The BioAgTech World Congress is produced 'by the BioAg industry and for the BioAg industry' with the objective of enabling face-to-face networking and presentations on the latest technological advances within the industry. With approximately 1,300 attendees and 250 companies anticipated to be in attendance, BioAgTech World Congress serves as a meeting venue for leading industry innovators.
Chad Pawlak, Chief Executive Officer of Genvor, will participate in one-on-one meetings with industry participants, investors and the media throughout the conference.
5th BioAgTech World Congress
Date: April 22-26, 2024
Location: Raleigh Convention Center | Raleigh, North Carolina
For more information or to register for the event, please visit the conference website. To schedule a one-on-one meeting at the conference, please email your request to GNVR@mzgroup.us or call Lucas Zimmerman at (949) 259-4987.
About Genvor
Genvor Incorporated (OTCQB:GNVR) is a developer of sustainable plant health solutions, with a portfolio of patented peptides to provide crops with anti-pathogen and enhanced nutritional properties through next-generation biological foliar application as well as transgenic seed traits. Supported by globally renowned scientists and a USDA partnership, Genvor leverages its licensing-first business model with active trait developments underway for a variety of crops including corn, citrus, rice, cotton, soybean, flax, and potato. To learn more, please visit www.genvor.com or follow us on LinkedIn, Facebook or Instagram.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include information about management's view of the Company's future expectations, plans and prospects, including future business opportunities or strategies and are generally preceded by words such as "may," "believe," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of known and unknown risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Certain of these risk factors and others are included in documents the Company files with the Securities and Exchange Commission, including but not limited to, the Company's most recent Annual Report on Form 10-K, as well as the Company's other reports filed with the Securities and Exchange Commission.
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
GNVR@mzgroup.us
www.mzgroup.us
SOURCE: Genvor Incorporated
View the original press release on accesswire.com
FAQ
When is the 5th BioAgTech World Congress taking place?
Where is the BioAgTech World Congress being held?
Who will be participating from Genvor (GNVR) at the conference?
How can one schedule a one-on-one meeting at the conference with Genvor (GNVR)?
